Skip to main content

Table 2 Hematological and organ responses

From: Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial

ITT

Months post HDM/SCT

3

3

12

12

24

24

BD + HDM/SCT

HDM/SCT

BD + HDM/SCT

HDM/SCT

BD + HDM/SCT

HDM/SCT

 

Number = 28

Number = 28

Number = 28

Number = 28

Number = 20

Number = 23

CR

15 (53.6%)a

6 (21.4%)

19 (67.9%)a

10 (35.7%)

14 (70%)a

8 (34.8%)

VGPR

4 (14.3%)

4 (14.3%)

2 (7.1%)

3 (10.7%)

1 (5%)

1(4.3%)

PR

3 (10.7%)

4 (14.3%)

3 (10.7%)

2(2.1%)

1 (5%)

2 (8.7%)

NR

6 (21.4%)

12 (42.8%)

2 (7.1%)

6 (21.4%)

2 (10%)

3 (13.0%)

PD

-

-

2 (7.1%)

3 (10.7%)

1 (5%)

3 (13.0%)

Organ responses

Kidneyb

  

65.2% (15/23)

39.1% (9/23)

75% (12/16)

53.8% (7/13)

Heartb

  

67% (10/15)

25% (4/12)

70% (7/10)

50% (3/6)

Liverb

  

100% (1/1)

50% (1/2)

100% (1/1)

100% (1/1)

NSb

  

100% (3/3)

100% (2/2)

100% (3/3)

100% (2/2)

  1. aCompared with the HDM/SCT group, P <0.05; bevaluable patients. CR, complete hematological response; ITT, intention-to-treat; NR, no response; NS, nervous system; PD, disease progression; PR, partial response; SD, stable disease; VGPR, very good partial response.